Authors
Latest:
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected DataAlberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Latest:
Ubamatamab, Anti-PD-1 ICI, May Bolster Immune Response in Kidney CancerA phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Latest:
Abdulraheem Yacoub, MD, on Advancing Outcomes for Patients With Myelofibrosis and Myeloproliferative NeoplasmsCancerNetwork® spoke with Abdulraheem Yacoub, MD, during the American Association for Cancer Research Annual Meeting 2021 to discuss how predictors of response to therapy may be just as important as the development of new therapies for advancing outcomes in myelofibrosis and myeloproliferative neoplasms.
Latest:
Extranodal NK/T-Cell Lymphoma Misdiagnosed as Pulmonary InfectionThis case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.
Latest:
Expert Commentary on the Product Profile of Margetuximab for HER2-Positive Breast CancerIn an interview with ONCOLOGY®, Sandra Cuellar, PharmD, BCOP, FASHP, offers a comprehensive review of real-world treatment considerations of margetuximab as therapy for adult patients with metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2 regimens with at least 1 being for metastatic disease.
Latest:
Retrospective Radiotherapy in IBD Data May Warrant Prospective ResearchRetrospective study data show that patients with inflammatory bowel disease may not require modification of standard radiotherapy for pelvic malignancies.
Latest:
Nadofaragene Firadenovec Results in uMRD-Negative Status in NMBICuMRD-negative status linked to recurrence-free outcomes with nadofaragene firadenovec in NMIBC
Latest:
The Future of Immunotherapy in Low-Grade Serous Ovarian Cancer TreatmentThe panel explains how low-grade serous ovarian cancer differs from high-grade, and if an immunotherapy approach is appropriate for treatment.
Latest:
The Role of Artificial Intelligence in Enhancing Precision Medicine for NSCLCAI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.
Latest:
Molecular Characterization of a Rare Glioblastoma Case With Atypical Histopathologic FeaturesA patient case of a 76-year-old man with a rare glioblastoma variant showcased the importance of molecular profiling in diagnosing and guiding treatment for brain tumors.
Latest:
Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous SystemAnaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.
Latest:
Cross Q&A: Role of Belantamab Mafodotin in MMThe panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.
Latest:
Translating CLL Trial Success to Real-World Treatment ApplicationYale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Latest:
R/R MM: Bispecifics in R/R MM: Key TakeawaysPanelists discuss how to manage talquetamab-associated adverse events, such as skin toxicities and dysgeusia, sharing their clinical experience with toxicity timing, frequency, and key strategies for fellow oncologists implementing bispecific antibodies in relapsed/refractory multiple myeloma.
Latest:
Future Perspectives: What’s Next in NDMM?Panelists discuss how the treatment landscape for patients with transplant-ineligible/deferred newly diagnosed multiple myeloma (NDMM) is expected to evolve, with considerations for optimizing therapeutic approaches based on emerging data from novel drug combinations and treatment strategies.
Latest:
Best Treatment Selection in Clear-Cell RCCMedical experts describe the decision-making process between choosing an IO-IO vs an IO-TKI regimen for first-line treatment, considering factors such as safety profile and response in both community and academic settings.
Latest:
ONCOLOGY® Looks to Conference Agendas for Current Trends"Witnessing the resiliency of the oncology community in the face of challenges to both patients and their providers builds momentum in the community and is sure to lead to better outcomes going forward."
Latest:
ACRO Issues Statement on 2026 Physician Fee Schedule Final RuleDue to certain errors in the 2026 PFS Final Rule pre-publication, ACRO has issued a statement while awaiting the publication of the 2026 HOPPS Final Rule.
Latest:
Radiopharmaceutical Agent Shows Efficacy, Tolerability in SSTR2+ NETsBrandon R. Mancini, MD, MBA, FACRO, discussed results from a phase 1/2a trial that evaluated [212Pb]VMT-α-NET in patients with advanced NETs.
